| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00626210 Details | 2019-10-28 Interventional | 4 | 2 | Modafinil Alzheimer Disea… Sleep Initiatio… Insomnia | - Early termination leading to small numbers of subjects analyzed | |||
| NCT03028129 Details | 2019-10-25 Interventional | 4 | 467 | Anti-Bacterial … Isoniazid Tuberculosis Tuberculosis, P… Antibiotic Prop… | Interim analysis showed efficacy less than 2.5%. Loss to follow-up Interruption of the study Arms presented differential group allocation Statistical power to detect the primary endpoint was 73%, lower than estimated in our sample size calculation | |||
| NCT02124850 Details | 2019-10-25 Interventional | 1 | [1 Refs] | 18 | Cetuximab Nivolumab Squamous Cell C… Squamous Cell C… | - - | ||
| NCT02408328 Details | 2019-10-24 Interventional | 2 | 0 | Caffeine Caffeine citrat… Apnea | Transition to new position - | |||
| NCT04012255 2018-003923-13 Details | 2019-10-23 Interventional | 1 | 29 | Semaglutide Obesity Overweight | The trial was terminated for strategic reasons. - | |||
| NCT03996486 2018-004566-34 Details | 2019-10-22 Interventional | 1 | 0 | Antibodies, Mon… Immunoglobulin … Immunoglobulins Lipoprotein-ass… Myeloma Protein… Paraproteins Hemophilia A Hemophilia | Company decision - | |||
| NCT03080480 Details | 2019-10-22 Interventional | 1/2 | 3 | Pioglitazone Granuloma Granulomatous D… Chronic Granulo… | The results are negtive. - | |||
| NCT01729104 Details | 2019-10-22 Interventional | 1 | 18 | Lenalidomide Rituximab Lymphoma | Low response - | |||
| NCT00866333 Details | 2019-10-22 Interventional | 2 | 49 | Entinostat Hodgkin Disease Lymphoma Hodgkin's Lymph… | Terminated prior to completion of accrual per corporate decision. - | |||
| NCT02500901 Details | 2019-10-21 Interventional | 1 | 2 | Niraparib Prostatic Neopl… Metastatic Pros… | Suspended by funder Study was terminated early by the funder. | |||
| NCT01766336 2012-005524-15 Details | 2019-10-21 Interventional | 2 | 296 | Inositol Aggression Alzheimer Disea… Psychomotor Agi… Alzheimer's Dis… | - - | |||
| NCT01674010 2012-001935-30 Details | 2019-10-21 Interventional | 2 | 309 | Inositol Lamotrigine Valproic Acid Bipolar 1 Disor… | Business Decision - | |||
| NCT03316339 Details | 2019-10-18 Interventional | 3 | 316 | Dexmedetomidine Remifentanil Opioid-Related … Anesthesia | Sponsor's decision - | |||
| NCT03281681 Details | 2019-10-18 Interventional | 1/2 | 0 | Dianhydrogalact… Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | Alternate study design for ovarian cancer under discussion - | |||
| NCT00407407 NCT00405223 Details | 2019-10-18 Interventional | 1 | 6 | Albumin-Bound P… Carboplatin Carcinoma Fallopian Tube … Neoplasms Ovarian Neoplas… Peritoneal Neop… | MTD not determined - | |||
| NCT04130399 Details | 2019-10-17 Interventional | 2 | 0 | Folfirinox Pancreatic Neop… Pancreatic Aden… Pancreatic Canc… | Study is being abandoned. - | |||
| NCT02192697 Details | 2019-10-17 Interventional | 1/2 | 124 | Naquotinib Carcinoma, Non-… Lung Neoplasms Non-small Cell … | Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies. - | |||
| NCT01747499 Details | 2019-10-16 Interventional | 1/2 | 54 | Azacitidine Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Precursor Cell … | Enrolling 8 more patients would be statistically unlikely that the primary endpoint would be
reached (reduce day 180 grade II-IV GVHD rates to 20% or less) - | |||
| NCT03125187 Details | 2019-10-15 Interventional | 1 | - | Calcium heparin Heparin Heparin | Delay in the R&D stage - | |||
| NCT02657369 2015-001929-17 Details | 2019-10-15 Interventional | 2 | 34 | Lenvatinib Carcinoma Thyroid Carcino… Thyroid Disease… Thyroid Neoplas… | Overall response rate was 3% (only 1 out of 33 participants had confirmed PR). The study was terminated since overall response rate was 3% (only 1 out of 33 participants had confirmed PR). |